Subramaniam Sangeetha, Mehrotra Monica, Gupta Dinesh
Bioinformatics Laboratory, Structural and Computational Biology Group, International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi, India.
Comb Chem High Throughput Screen. 2011 Dec;14(10):898-907. doi: 10.2174/138620711797537058.
The emergence and spread of Plasmodium falciparum resistance to existing antimalarials emphasize the impelling search for novel drug targets and chemotherapeutic compounds. The ubiquitin-proteasome system plays a major role in overall protein turnover, in eukaryotic cells including plasmodia. 20S β subunit is the catalytic core of this proteolytic machinery, and hence most of the inhibitors developed are being targeted towards this component. Inhibition of the proteasome is established as a promising strategy to develop novel antimalarial drugs. The present study reports identification of novel drug-like 20S proteasome inhibitors with potential activity against the 20S β subunit of P. falciparum using a combination of ligand based (Support Vector Machines) and receptor based (molecular docking) techniques. The robust learning and generalizing capability of Support Vector Machines (SVM) has been exploited to classify proteasome inhibitors and non-inhibitors, targeted towards P. falciparum 20S proteasome. SVM model has been trained using 170 molecular descriptors of 64 inhibitors and 208 putative non-inhibitors of 20S proteasome. The non-linear classifier based on Radial Basis Function (RBF) kernel yielded highest classification accuracy in comparison to the linear classifier. The best classifier had 5-fold Cross-Validation (CV) accuracy of 97% and Area Under Curve (AUC) of 0.99 reflecting good accuracy of the model. The SVM model rapidly classified compounds with potential proteasomal activity. Subsequently, molecular docking studies aided the generation of focused collection of compounds with good binding affinity towards the substrate-binding site of 20S β subunit. The novel drug-like 20S proteasome inhibitors identified in this study can be a good starting point to develop novel antimalarial drugs.
恶性疟原虫对现有抗疟药物产生耐药性并传播,这凸显了迫切需要寻找新的药物靶点和化疗化合物。泛素 - 蛋白酶体系统在包括疟原虫在内的真核细胞的整体蛋白质周转中起主要作用。20Sβ亚基是这种蛋白水解机制的催化核心,因此开发的大多数抑制剂都针对该组分。抑制蛋白酶体已被确立为开发新型抗疟药物的一种有前景的策略。本研究报告了使用基于配体(支持向量机)和基于受体(分子对接)技术相结合的方法,鉴定出对恶性疟原虫20Sβ亚基具有潜在活性的新型类药物20S蛋白酶体抑制剂。支持向量机(SVM)强大的学习和泛化能力已被用于对针对恶性疟原虫20S蛋白酶体的蛋白酶体抑制剂和非抑制剂进行分类。使用20S蛋白酶体的64种抑制剂和208种推定的非抑制剂的170个分子描述符对SVM模型进行了训练。与线性分类器相比,基于径向基函数(RBF)核的非线性分类器产生了最高的分类准确率。最佳分类器的5倍交叉验证(CV)准确率为97%,曲线下面积(AUC)为0.99,反映了模型的良好准确性。SVM模型快速对具有潜在蛋白酶体活性的化合物进行了分类。随后,分子对接研究有助于生成对20Sβ亚基底物结合位点具有良好结合亲和力的化合物的聚焦集合。本研究中鉴定出的新型类药物20S蛋白酶体抑制剂可以成为开发新型抗疟药物的良好起点。